Saxenda (liraglutide): daily weight loss injection
Saxenda contains liraglutide, a GLP-1 receptor agonist, and is authorised for weight management together with a reduced-calorie diet and more physical activity. Unlike the newer medicines in this group, which are injected once a week, it is injected once a day. It is a medicine subject to medical prescription, because whether medical treatment of weight is justified and safe has to be judged for each person. This page sets out the doses, the side effects and what we can and cannot do.
What Saxenda is and which active substance it contains
Saxenda contains liraglutide, an analogue of glucagon-like peptide 1 (GLP-1), one of the body's own hormones; the product information describes GLP-1 as a physiological regulator of appetite and food intake. Saxenda is authorised centrally for the European Union, and its product information is published by the European Medicines Agency.
It comes as a pre-filled pen for injection under the skin. One pen holds 18 mg of liraglutide in 3 ml and can deliver doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg and 3.0 mg; after first use the pen is discarded after 1 month. It is not a tablet and it is not insulin.
The same substance is in other EU products with a different purpose: Victoza is liraglutide authorised for type 2 diabetes, and liraglutide is also combined with insulin degludec in another product. Same substance, different names, different uses and different strengths: swapping one product for another is not justified in itself, and that decision belongs to a doctor. The whole group is compared in our overview of GLP-1 medicines.
Who this treatment is intended for
In adults, Saxenda is authorised for weight management when the starting body mass index (BMI) is 30 or more, or 27 to under 30 with at least one weight-related condition, such as prediabetes or type 2 diabetes, high blood pressure, disturbed blood fats or obstructive sleep apnoea. What the BMI figures mean is explained in our guide to obesity and BMI.
The product information also covers adolescents from 12 years with obesity and a body weight above 60 kg, and children from 6 to under 12 years with obesity and a body weight of at least 45 kg; in children, treatment is started by a doctor experienced in managing obesity in children. For a child or adolescent, the assessment belongs with a doctor who examines the patient in person and can follow them up, and our questionnaire is not a suitable route for a first assessment of that kind.
This is not a medicine for cosmetic weight reduction in someone of healthy weight, and it is not a short course before a particular date. The product information names groups in whom use is not recommended, among them people aged 75 or more, people using other weight management products and people whose weight gain is caused by a hormonal or eating disorder or by another medicine.
Doses in the product information
Treatment starts at 0.6 mg once a day and rises by 0.6 mg at intervals of at least one week until the maintenance dose of 3.0 mg a day is reached, which is meant to improve digestive tolerability. Daily doses higher than 3.0 mg are not recommended. If the next step is not tolerated for two weeks in a row, the product information says to consider stopping treatment. Your own steps are set by the doctor.
If you forget a dose and remember within 12 hours, inject it; if more than 12 hours have passed, skip it and inject the next dose the following day at the usual time, without a double dose. Never share your pen or needles with other people, and do not stop using Saxenda without talking to the doctor.
The product information also sets a point for deciding whether to continue. In adults, treatment is stopped after 12 weeks on 3.0 mg a day if at least 5% of the starting body weight has not been lost. In adolescents and children, it is stopped and re-evaluated if the BMI, or the BMI z score, has not fallen by at least 4% after 12 weeks on 3.0 mg or the highest dose tolerated.
| Week | Daily dose |
|---|---|
| Week 1 | 0.6 mg |
| Week 2 | 1.2 mg |
| Week 3 | 1.8 mg |
| Week 4 | 2.4 mg |
| From week 5 (maintenance) | 3.0 mg |
Once a day or once a week: how Saxenda compares
Liraglutide acts for a shorter time in the body than semaglutide and tirzepatide, so Saxenda is injected every day, while the newer medicines are injected once a week. That is a difference in the substance, not a difference in quality, and it is one of the things a doctor weighs up alongside tolerance, other conditions and what you have already tried. More about the weekly injections is on the tirzepatide page and on the semaglutide page, which also explains which semaglutide products are for type 2 diabetes only.
| Point of comparison | Liraglutide (this page) | Semaglutide and tirzepatide |
|---|---|---|
| How often | Once a day, at any time, preferably around the same time each day | Once a week, on a chosen day that can be moved if at least 3 days separate two doses |
| Building up the dose | Weekly steps to 3.0 mg, about 4 weeks in total | Steps of at least 4 weeks; about 16 weeks to the semaglutide maintenance dose |
| A missed dose | Taken if no more than 12 hours late; otherwise skipped | Taken within 5 days (semaglutide) or 4 days (tirzepatide); otherwise skipped |
| Point for deciding whether to continue in adults | After 12 weeks on 3.0 mg, with at least 5% weight loss | No fixed stopping point for adults in their product information |
How liraglutide works
Liraglutide binds to and activates the GLP-1 receptor. According to the product information, it regulates appetite by increasing the feeling of fullness and lowering hunger, which leads to eating less; it does not increase the energy the body uses. The weight lost is mainly fat.
It also stimulates the release of insulin and lowers the release of glucagon in a glucose-dependent way, that is, mainly when blood sugar is raised, which is why blood sugar can change during treatment. The effect on blood sugar is more pronounced in people with prediabetes or diabetes.
The substance slows the emptying of the stomach, which reinforces the feeling of fullness and at the same time explains the digestive complaints that are most common at the start of treatment. The full effect is not there at the start, because treatment begins at a low dose; whether the treatment is working is judged by the doctor from measurements taken over a longer period.
Side effects and when to contact a doctor
Digestive reactions are the most frequently reported side effects: nausea, vomiting, diarrhoea and constipation, together with indigestion, dry mouth, reflux, upper abdominal pain, wind, burping and bloating. They are strongest at the start and after each step up and settle for most people. Smaller portions, eating slowly and avoiding very fatty food help.
Headache, dizziness, changes in taste, difficulty sleeping (mainly in the first 3 months), tiredness and reactions at the injection site are also described. Change the injection site every time: the product information links this with a lower risk of amyloid deposits under the skin.
Liraglutide can raise the resting heart rate. Palpitations or a racing heartbeat at rest are worth reporting; if the rise is sustained, treatment is stopped. Gallstones and inflammation of the gallbladder occurred more often with liraglutide than with placebo in the weight management studies, so pain in the right upper abdomen is a reason to contact a doctor. Vomiting and diarrhoea can lead to dehydration, which can affect the kidneys, so drink enough.
Stop the medicine and seek medical help in the case of severe and persistent abdominal pain, especially spreading to the back and with vomiting, because acute pancreatitis is a recognised risk, or signs of an allergic reaction such as swelling of the face, lips or throat and difficulty breathing. In an emergency, call 112.
Before any procedure under general anaesthesia or deep sedation, including a gastroscopy or a colonoscopy done under sedation, tell the team that you use this medicine: cases of pulmonary aspiration have been reported with GLP-1 receptor agonists, because food can stay in the stomach for longer than expected. Say so even when the procedure has been arranged at short notice. The full list of side effects is in the leaflet in your pack.
Interactions, alcohol and when the medicine is not suitable
Slower stomach emptying can affect how medicines taken by mouth are absorbed. For most of them it makes no practical difference, but a doctor takes it into account for medicines with a narrow safety margin. Bring a complete list of what you take, including products bought without a prescription, supplements and herbal preparations.
Where insulin or a sulfonylurea is used at the same time, the risk of low blood sugar is higher, so a doctor usually lowers those doses, and blood sugar self-monitoring is needed to adjust them. Saxenda must not replace insulin, and it is not combined with another GLP-1 receptor agonist. For combined contraceptive pills, the product information expects the contraceptive effect to be unaffected; severe vomiting and diarrhoea can still make a pill less reliable, so mention it in the assessment.
Alcohol adds calories, works against the aim of the treatment and makes the digestive complaints worse. It also lowers blood sugar in a delayed way, which matters if you also use insulin or a sulfonylurea.
The only contraindication in the product information is an allergy to liraglutide or to an ingredient, but use is not recommended in severe kidney or liver disease, inflammatory bowel disease, diabetic gastroparesis or the most severe heart failure, and caution is needed with thyroid disease. A past inflammation of the pancreas, gallbladder disease, an eating disorder and a family history of rare thyroid and endocrine disease also need to be raised before a prescription, not after.
Pregnancy and breastfeeding
Liraglutide should not be used during pregnancy. If you wish to become pregnant, or become pregnant, treatment is stopped. Because experience is lacking, Saxenda should not be used while breastfeeding either. We do not start this treatment in pregnancy, when you are planning a pregnancy or while you are breastfeeding. If you could become pregnant, raise contraception with the doctor.
Prescription status, cover and the price at the pharmacy
Saxenda is a medicine subject to medical prescription: that is its classification in Annex II B of the EU product information. A pharmacy therefore supplies it only against a prescription, and the decision to prescribe belongs to a doctor after an assessment of your medical information.
The price of Saxenda in Malta is set by the pharmacy and depends on the pack, so we do not quote it, and the pharmacy is the place to ask. It is not an ePrescription and does not appear in myHealth; it is outside POYC and the Government Formulary List, and you pay for the medicine at the pharmacy in full. Our fee for the doctor's review is a separate item and never includes the medicine.
The Medicines Authority states that in Malta "all medicinal products are dispensed only from pharmacies". A pen offered outside a pharmacy may be falsified.
What happens online and what does not
Online, only the doctor's review takes place; we do not sell or send medicines. Whether you are starting Saxenda or continuing it, a request goes through our Weight Loss Treatment service. You fill in a medical questionnaire about the medicine, your health and other medicines you take, and the doctor reviews it in writing.
If the doctor has questions, they ask them in writing in the chat in your account, and you get an email to let you know. There is no video call, no phone call and no live chat. A first prescription can be considered only where your answers show clear indications and no contraindications: the doctor may then ask for up-to-date weight and height or recent results, recommend that you see a doctor in person, or decline. For some conditions, and in some individual cases, it is advisable to see a doctor in person; the doctor may recommend this.
If the doctor issues a prescription, you receive it as a PDF by email. You print it and bring it on paper to a pharmacy in Malta together with photo identification. Your prescription is issued in the standard EU cross-border format set out in Directive 2012/52/EU. A pharmacy in Malta may dispense it; the decision rests with the pharmacist. Take the prescription to a pharmacy within six months of the date on it; a prescription for an antibiotic cannot be dispensed more than ten days after its date of issue.
The fee covers the medical consultation, not the issuing of a document. If the doctor declines on medical or legal grounds, we refund the fee. If the doctor asks you for documents, you have at least 7 days to send them in and we send you a reminder; if you ask us, we agree a longer deadline. If the case still cannot be completed, we close the request, let you know and refund the fee in full.
Who reviews your request?
Every request is reviewed by one doctor: Damian Wojno, a doctor registered with the Polish Medical Chamber, licence no. 3211301. The doctor is not registered with the Medical Council of Malta. We do not prescribe opioids, benzodiazepines, Z-drugs, stimulants, gabapentinoids or medical cannabis. This is our own rule and goes further than the Maltese lists of controlled drugs. Liraglutide is not affected by it.
Is Saxenda prescription only in Malta?
Saxenda has a central EU authorisation, and its product information (Annex II B) classifies it as a medicine subject to medical prescription. A pharmacy supplies it only against a prescription, because a doctor has to judge whether medical treatment of weight is justified and safe in your case and at which dose to start. A review can also end in a refusal.
What doses does Saxenda come in?
One pen can deliver 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg and 3.0 mg. Treatment starts at 0.6 mg a day and rises by 0.6 mg at least a week apart to the maintenance dose of 3.0 mg a day; higher daily doses are not recommended. Your own steps are set by the doctor.
When should Saxenda be stopped?
The product information says that in adults treatment is stopped after 12 weeks on 3.0 mg a day if at least 5% of the starting body weight has not been lost. It is also stopped if pancreatitis is suspected, if pregnancy is planned or occurs, or if the resting heart rate stays clearly raised. Any stop or pause is agreed with the doctor.
Which side effects of Saxenda are common?
Nausea, vomiting, diarrhoea, constipation, indigestion and bloating are the most common, and they are strongest at the start and after each step up. Headache, dizziness, difficulty sleeping, tiredness and reactions at the injection site are also described. Severe abdominal pain spreading to the back, pain in the right upper abdomen and palpitations at rest are reasons to contact a doctor. The full list is in the leaflet for your pack.
Why is Saxenda injected every day when other injections are weekly?
Liraglutide acts for a shorter time in the body than semaglutide and tirzepatide, so it is used on a daily rhythm while they are used weekly. That is a difference in the substance, not a difference in quality, and it is one of the things a doctor weighs up alongside tolerance, other conditions and what you have already tried.
Is alcohol allowed with Saxenda?
There is no direct incompatibility, but alcohol adds calories, works against the aim of the treatment, irritates a digestive system that is already more sensitive and lowers blood sugar in a delayed way. If you also use insulin or a sulfonylurea, the risk of low blood sugar is higher. Discuss the amount with the doctor who is following you.
Can Saxenda be prescribed online?
The doctor can review a request through our Weight Loss Treatment service, whether you are starting or continuing, but a review is not a promise of a prescription. A first prescription needs clear indications and no contraindications in your answers; the doctor may ask for up-to-date measurements or recent results, recommend that you see a doctor in person, or decline. The medicine itself is dispensed only by a pharmacy. We do not promise a deadline.
- EMA: Saxenda (liraglutide), European public assessment report
- EMA: Saxenda product information, sections 4.1-4.6, 4.8, 5.1, 6.3, 6.5 and Annex II B
- EMA: Victoza (liraglutide) product information, section 4.1
- Medicines Authority: prescription-only and non-prescription medicines, validity of prescriptions
- Medicines Act (Cap. 458), Article 81(3) (legislation.mt)
- Prescription and Dispensing Requirements Rules (S.L. 458.49), rule 4 (legislation.mt)
- Commission Implementing Directive 2012/52/EU (EUR-Lex, English)